Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
Strasbourg, France, March 15, 2018, 7:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, will be presenting a poster with new and encouraging preclinical data on a novel viral vector (pseudocowpox, PCPV) at the AACR (American Association for Cancer Research) Annual Meeting 2018, Chicago, IL, USA, April 14 – 18.
The abstract was accepted for a late-breaking session of the congress and will be made available on the AACR Online Itinerary Planner and Meeting App on April 13, 2018.
Poster title: Pseudocowpox: A next generation viral vector for cancer immunotherapy. A poxviral vector selected for its remarkable ability to induce IFN-alpha.
• Session Title: Late-Breaking Research: Immunology 2
• Poster and abstract number: LB-287
• Date, time, location: Tuesday Apr 17, 2018 1:00 PM - 5:00 PM, Poster Section 44, Board 8
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer